Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

[Whipple disease revealed by anti-TNFα therapy].

Sparsa L, Fenollar F, Gossec L, Leone J, Pennaforte JL, Dougados M, Roux C.

Rev Med Interne. 2013 Feb;34(2):105-9. doi: 10.1016/j.revmed.2012.10.371. Epub 2012 Nov 28. French.

PMID:
23199973
2.

Whipple's disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature.

Ramos JM, Pasquau F, Galipienso N, Valero B, Navarro A, Martinez A, Rosas J, Gutiérrez A, Sanchez-Martínez R.

J Med Case Rep. 2015 Jul 28;9:165. doi: 10.1186/s13256-015-0632-6. Review.

4.

Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.

Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.

J Clin Immunol. 2008 Sep;28(5):445-55. doi: 10.1007/s10875-008-9214-3. Epub 2008 Jun 28.

PMID:
18587633
5.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
6.

Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.

Moltó A, Paternotte S, Claudepierre P, Breban M, Dougados M.

Arthritis Rheumatol. 2014 Jul;66(7):1734-44. doi: 10.1002/art.38613.

7.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

8.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
9.

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

PMID:
21789614
10.

Whipple's disease diagnosed during biological treatment for joint disease.

Hoppé E, Masson C, Audran M, Drillon M, Andreu M, Saraux A, Berthelot JM, Maugars Y, Hmamouchi I, Morel J.

Joint Bone Spine. 2010 Jul;77(4):335-9. doi: 10.1016/j.jbspin.2010.03.015. Epub 2010 May 14.

PMID:
20471891
11.

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST.

Clin Rheumatol. 2012 Apr;31(4):631-6. doi: 10.1007/s10067-011-1895-y. Epub 2011 Nov 18.

PMID:
22147207
12.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
13.

[Non tuberculous anti-TNF associated opportunistic infections].

Marie I, Guglielmino E.

Rev Med Interne. 2010 May;31(5):353-60. doi: 10.1016/j.revmed.2009.04.010. Epub 2010 Apr 8. French.

PMID:
20381217
14.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
15.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
16.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

17.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.

Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2. Review.

PMID:
22296031
18.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
19.

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.

Massara A, Cavazzini L, La Corte R, Trotta F.

Semin Arthritis Rheum. 2010 Feb;39(4):313-9. doi: 10.1016/j.semarthrit.2008.11.003. Epub 2009 Jan 15. Review.

PMID:
19147181
20.

Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

Costa MF, Said NR, Zimmermann B.

Semin Arthritis Rheum. 2008 Jun;37(6):381-7. Epub 2007 Oct 30. Review.

PMID:
17977585

Supplemental Content

Support Center